Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christine Wyszomirski

Physician Assistant Lindenhurst, IL Physician Assistant

NPI 1770642258 CMS profile 11224955

3021 Falling Waters Blvd Ste A, Lindenhurst, IL 60046

Open in the dashboard

General payments

$8,186

422 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christine Wyszomirski of Lindenhurst, IL is reported in the CMS Open Payments database as having received $8,186 across 422 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,608 72
2024 General $1,570 78
2023 General $1,663 81
2022 General $1,758 96
2021 General $1,588 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christine Wyszomirski
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Christine Wyszomirski were reported at $1,608. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Christine Wyszomirski Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,588 $132 $37–$438 $132
2022 $1,758 $155 $48–$522 $149
2023 $1,663 $167 $52–$557 $160
2024 $1,570 $178 $55–$600 $164
2025 $1,608 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,121 54 payments
  2. Lilly USA, LLC $886 49 payments
  3. AstraZeneca Pharmaceuticals LP $791 46 payments
  4. Pfizer Inc. $693 30 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $531 25 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $463 30 payments
  7. AbbVie, Inc. $413 20 payments
  8. Merck Sharp & Dohme Corporation $413 24 payments
  9. Amgen Inc. $302 16 payments
  10. Exact Sciences Corporation $271 13 payments
  11. Other $2,302 115 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,186 422 payments
Products named General payments · program years 2021–2025
  1. MOUNJARO $544 27 payments
  2. Ozempic $391 20 payments
  3. GARDASIL 9 $389 23 payments
  4. NURTEC ODT Pain $367 16 payments
  5. RYBELSUS $364 18 payments
  6. NURTEC ODT Primary Care $348 17 payments
  7. ZAVZPRET $322 14 payments
  8. FARXIGA $315 19 payments
  9. COMIRNATY $308 13 payments
  10. VYVANSE $300 20 payments
  11. Other $7,937 405 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

702

Median for Physician Assistant: 241

Drug cost

$49,970

Median for Physician Assistant: $4,110

Branded share of claims

12.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 25 $28,386
Farxiga Dapagliflozin Propanediol Brand 15 $13,886
Atorvastatin Calcium Generic 100 $880
Losartan Potassium Generic 61 $598
Levothyroxine Sodium Generic 51 $587
Rosuvastatin Calcium Generic 60 $520
Synthroid Levothyroxine Sodium Brand 12 $504
Metformin Hcl Generic 34 $501
Olmesartan Medoxomil Generic 17 $461
Metoprolol Succinate Generic 25 $440

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$17,079

Of which drugs: $3,402

Medicare patients

106

Average age 71

Services billed

320

70 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 30%
Diabetes 28%
Ischemic heart disease 14%
Chronic kidney disease 12%
Depression 11%
Osteoporosis 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $145
$145 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $138
$138 — —
Veozah
  • Astellas Pharma US Inc $92
$92 — —
Wegovy
  • Novo Nordisk Inc $85
$85 — —
JARDIANCE
  • Lilly USA, LLC $52
  • Boehringer Ingelheim Pharmaceuticals, Inc. $30
$82 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

422 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record